HUAREN MEDICAL TECHNOLOGY

R & D SERVICES

Home page

Preclinical CRO

Basic Scientific Research

Preclinical CRO

CDMO Services for Cell Therapy Products

Preclinical CRO

Pharma CRDMO
( Contract research, development and production )

Preclinical Animal Testing

R&D Pipeline
Gene Therapy

R&D Pipeline

We provide integrated CRDMO services (Contract Research, Development and Manufacturing Organization) from drug discovery to commercial production combining traditional CRO (Contract Research Organization) services, CDMO (Contract Development and Manufacturing Organization) services and CMO (Contract Manufacturing Organization) services under the same platform.

• Chimeric Antigen Receptor T Cells (CAR-T)

Huaren Medical is actively developing cutting-edge CAR-T cell therapies to address unmet needs in oncology.

CAR-T Cells are genetically engineered T cells that express chimeric antigen receptors (CAR), a fusion protein that contains three components: the tandem antigen-binding structural domain of the antibody, the transmembrane structural domain, and the signaling element of the T-cell receptor complex. The CAR antigen-binding structural domain searches for tumor cells that express surface antigens of the target cell, and once a CAR has found the target, a molecular signals will be sent to activate the CAR-T cell through its intracellular module, which leads to the destruction of the target tumor cell.

• Natural killer cell therapy (CAR-NK)

We are developing a natural killer cell (NK) based allogeneic CAR platform

NK cells are the body's first line of defense against virally infected cells or tumor cells. CAR-NK cells do not need to be initiated and have a variety of mechanisms for triggering a response to tumors that are not limited to direct release of cytotoxic particles, antibody-dependent cellular cytotoxicity (ADCC), CAR-mediated killing, and secretion of inflammatory cytokines.
NK cells naturally recognize features associated with cellular stress that help facilitate targeting and elimination of tumor-specific cells. When NK cells are engineered to express CAR, their anti-tumor effects may be more pronounced.

• DC-CTL

DC cells are the most powerful antigen-presenting cells known in vivo. After large-scale expansion and culture in vitro and sensitization to tumor antigens, DC cells can be infused back into patients, which can induce the proliferation and differentiation of patients' T cells into cytotoxic T cells, and at the same time activate B lymphocytes, fully activating the antibody immune system to produce highly efficient and specific anti-tumor effects.
CTL cells, i.e. cytotoxic T-lymphocytes, have been the hotspot of immunotherapy for solid tumors (especially malignant melanoma, gastric cancer, colorectal cancer, hepatocellular carcinoma, prostate cancer, lung cancer, cervical cancer, etc., where tumor antigens are relatively clear), and its tumor-killing mechanism is clear, which is able to kill tumor cells directly by releasing two kinds of cytotoxins.

• Allogeneic Cell Therapies

We see the promise of allogeneic cell therapies and its potential benefits.
We are exploring a range of versatile tools and cell types in pursuit of true "off-the-shelf" cellular therapies.